Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin adjunctive therapy and oxidative stress biomarkers in systolic heart failure
IRCT20120215009014N486Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in heart failure (HF), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Change in serum oxidative stress biomarkers. Started Oct 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on IRCT20120215009014N486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N486.